SCHEDULE: FMR LLC & Abigail Johnson Boost 10x Genomics Stake

FMR LLC and Abigail P. Johnson report a 10.3% beneficial ownership stake in 10x Genomics, Inc. Class A Common Stock as of July 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson collectively hold 11,529,805.62 shares of 10x Genomics, Inc. Class A Common Stock.
• This beneficial ownership represents 10.3% of the outstanding Class A Common Stock.
• The reported shares include 892,772 shares of Class B Common Stock, which are convertible into Class A Common Stock at a 1:1 exchange rate.
• The 892,772 Class B shares represent 7.4144% of the outstanding Class B Common Stock.
• Assuming the conversion of all outstanding Class B Common Stock into Class A Common Stock, the reported 11,529,806 Class A shares would represent 9.3636% of the total outstanding Class A Common Stock.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of 10x Genomics, Inc., except for activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The filing is a standard beneficial ownership report (Schedule 13G Amendment), indicating a significant, but not new, stake by FMR LLC and Abigail P. Johnson. It does not contain performance data or strategic announcements that would typically drive strong positive or negative sentiment.

Positives

• A significant institutional investor, FMR LLC (Fidelity), maintains a substantial stake, indicating continued confidence in 10x Genomics, Inc.
• The beneficial ownership is held in the ordinary course of business, suggesting a long-term investment perspective rather than an activist stance.

Future Outlook

NA

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

This filing indicates continued institutional interest in the genomics and biotechnology sector, specifically in companies like 10x Genomics that provide tools for single-cell analysis and spatial genomics. It reflects a major asset manager's ongoing position in a key industry player.

Comparison to Industry Standards

• FMR LLC, as a major asset manager, frequently holds significant stakes (over 5%) in publicly traded companies across various industries, including biotechnology. This level of ownership is consistent with their role as a large institutional investor.
• The beneficial ownership structure, involving both Class A and convertible Class B shares, is common for companies with dual-class stock structures, often seen in tech and biotech firms to maintain founder/insider control while allowing public investment.

Corporate Governance

Related Party Transactions

• Abigail P. Johnson, as a Director, Chairman, and Chief Executive Officer of FMR LLC, and a member of the Johnson family (predominant owners of FMR LLC), is a related party to FMR LLC. Her beneficial ownership is reported alongside FMR LLC's, reflecting their interconnected interests.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional shareholder's stake, which can offer a degree of stability or confidence. The continued holding by FMR LLC suggests a long-term view.
• Management: Awareness of a large, stable institutional holder can influence management's strategic decisions, though the filing explicitly states the holding is not for control influence.

Key Dates

Keywords

10x Genomics, FMR LLC, Abigail P. Johnson, beneficial ownership, Schedule 13G, Class A Common Stock, institutional investment, SEC filing, biotechnology, genomics